205 related articles for article (PubMed ID: 34413148)
1. PET-Based Staging Is Cost-Effective in Early-Stage Follicular Lymphoma.
Lo AC; James LP; Prica A; Raymakers A; Peacock S; Qu M; Louie AV; Savage KJ; Sehn LH; Hodgson D; Yang JC; Eich HTT; Wirth A; Hunink MGM
J Nucl Med; 2022 Apr; 63(4):543-548. PubMed ID: 34413148
[TBL] [Abstract][Full Text] [Related]
2. A cost-utility analysis comparing CT surveillance, PET-CT surveillance, and planned postradiation neck dissection for advanced nodal HPV-positive oropharyngeal cancer.
Fu TS; Scheffler P; Forner D; Noel CW; Huang SH; Gilbert RW; Goldstein DP; O'Sullivan B; Mehanna HM; Waldron J; de Almeida JR
Cancer; 2021 Sep; 127(18):3372-3380. PubMed ID: 34062618
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the use of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in the workup of Staphylococcus aureus bacteraemia: a cost-utility analysis.
Ong SWX; Zhabokritsky A; Daneman N; Tong SYC; Wijeysundera HC
Clin Microbiol Infect; 2023 Nov; 29(11):1417-1423. PubMed ID: 37353076
[TBL] [Abstract][Full Text] [Related]
4. Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: A cost-effectiveness analysis.
Prica A; Chan K; Cheung M
Cancer; 2015 Aug; 121(15):2637-45. PubMed ID: 25877511
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of PET-CT-guided management for locally advanced head and neck cancer.
Smith AF; Hall PS; Hulme CT; Dunn JA; McConkey CC; Rahman JK; McCabe C; Mehanna H
Eur J Cancer; 2017 Nov; 85():6-14. PubMed ID: 28881249
[TBL] [Abstract][Full Text] [Related]
6. Elective neck dissection versus positron emission tomography-computed tomography-guided management of the neck in clinically node-negative early oral cavity cancer: A cost-utility analysis.
Noel CW; Forner D; Goldstein DP; Metser U; Ferris RL; Waldron J; de Almeida JR
Cancer; 2021 Jun; 127(12):1993-2002. PubMed ID: 33635537
[TBL] [Abstract][Full Text] [Related]
7. PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer.
Mehanna H; McConkey CC; Rahman JK; Wong WL; Smith AF; Nutting C; Hartley AG; Hall P; Hulme C; Patel DK; Zeidler SV; Robinson M; Sanghera B; Fresco L; Dunn JA
Health Technol Assess; 2017 Apr; 21(17):1-122. PubMed ID: 28409743
[TBL] [Abstract][Full Text] [Related]
8. A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphoma.
Tobin JWD; Crothers A; Ma TE; Mollee P; Gandhi MK; Scuffham P; Hapgood G
Leuk Lymphoma; 2021 Dec; 62(14):3484-3492. PubMed ID: 34323129
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma.
Fust K; Li X; Maschio M; Villa G; Parthan A; Barron R; Weinstein MC; Somers L; Hoefkens C; Lyman GH
Pharmacoeconomics; 2017 Apr; 35(4):425-438. PubMed ID: 27928760
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non-small Cell Lung Cancer in the Italian National Health Service.
Armeni P; Borsoi L; Fornaro G; Jommi C; Grossi F; Costa F
Clin Ther; 2020 May; 42(5):830-847. PubMed ID: 32354495
[TBL] [Abstract][Full Text] [Related]
11. Performing Gadoxetic Acid-Enhanced MRI After CT for Guiding Curative Treatment of Early-Stage Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
Suh CH; Kim KW; Park SH; Kim SY; Woo DC; Shin S; Pyo J; Shinagare AB; Ramaiya NH; Lim YS
AJR Am J Roentgenol; 2018 Feb; 210(2):W63-W69. PubMed ID: 29091004
[TBL] [Abstract][Full Text] [Related]
12.
Gassert FG; Rübenthaler J; Cyran CC; Rink JS; Schwarze V; Luitjens J; Gassert FT; Makowski MR; Schoenberg SO; Mayerhoefer ME; Tamandl D; Froelich MF
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3268-3276. PubMed ID: 33686457
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service.
Armeni P; Borsoi L; Fornaro G; Jommi C; Colombo N; Costa F
Clin Ther; 2020 Jul; 42(7):1192-1209.e12. PubMed ID: 32591103
[TBL] [Abstract][Full Text] [Related]
14. The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation.
Brush J; Boyd K; Chappell F; Crawford F; Dozier M; Fenwick E; Glanville J; McIntosh H; Renehan A; Weller D; Dunlop M
Health Technol Assess; 2011 Sep; 15(35):1-192, iii-iv. PubMed ID: 21958472
[TBL] [Abstract][Full Text] [Related]
15. An economic evaluation of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence.
Auguste P; Barton P; Hyde C; Roberts TE
Health Technol Assess; 2011 Apr; 15(18):iii-iv, 1-54. PubMed ID: 21524363
[TBL] [Abstract][Full Text] [Related]
16. Corneal Collagen Cross-Linking in the Management of Keratoconus in Canada: A Cost-Effectiveness Analysis.
Leung VC; Pechlivanoglou P; Chew HF; Hatch W
Ophthalmology; 2017 Aug; 124(8):1108-1119. PubMed ID: 28457614
[TBL] [Abstract][Full Text] [Related]
17. Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma.
Chen Q; Ayer T; Nastoupil LJ; Rose AC; Flowers CR
Value Health; 2015 Mar; 18(2):189-97. PubMed ID: 25773554
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the cost-effectiveness of [
Tew M; Douglas AP; Szer J; Bajel A; Harrison SJ; Tio SY; Worth LJ; Hicks RJ; Ritchie D; Slavin MA; Thursky KA; Dalziel K
Cancer Imaging; 2023 Dec; 23(1):119. PubMed ID: 38102639
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: a modelling study.
Vijenthira A; Chan K; Cheung MC; Prica A
Lancet Haematol; 2020 Feb; 7(2):e146-e156. PubMed ID: 31948928
[TBL] [Abstract][Full Text] [Related]
20. Outcome of patients with early-stage follicular lymphoma staged with
Ng SP; Khor R; Bressel M; MacManus M; Seymour JF; Hicks RJ; Wirth A
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):80-86. PubMed ID: 30083824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]